The Group posted a loss of £1.8 million, up from £0.4 million in the same period last year
LONDON: ImmuPharma PLC (LSE:IMM), a specialist in drug discovery and development, reported a widened interim loss for the six months ended June 30, 2025, as the company ramped up investment in its P140 autoimmune technology platform.
The Group posted a loss of £1.8 million, up from £0.4 million in the same period last year, driven by increased research and development costs, which rose to £0.7 million from £0.5 million. Administrative expenses edged up to £0.4 million, while a £0.7 million loss on revaluation of a derivative financial asset contrasted with a £0.2 million gain in 2024. Share-based payments totaled £0.05 million, compared with £0.03 million a year earlier.
Cash reserves fell to £0.4 million from £1.1 million, while the derivative financial asset rose to £0.6 million from £0.5 million. Basic and diluted loss per share widened to 0.38 pence, compared to 0.09 pence in the prior-year period.
Despite the financial setback, ImmuPharma announced key scientific milestones in its P140 platform, which targets autoimmune diseases. In January, the company unveiled preclinical findings that could enable earlier diagnostics and better patient selection for P140 therapy. In March, it confirmed evidence supporting the platform’s unique, non-immunosuppressive mechanism of action, reinforcing its safety and efficacy.
“These discoveries pave the way for P140 to become a new standard of care for multiple autoimmune conditions,” said CEO and Chairman Tim McCarthy. “We’re focused on advancing P140 for SLE and CIDP and securing global partnerships.”
The company is in active discussions with potential commercial partners and continues to expand its intellectual property portfolio. Its preclinical anti-infective programs, BioAMB and BioCIN, are progressing through studies. ImmuPharma also extended warrants in Incanthera to Sept. 30, 2025, with a profit-share agreement in place.
McCarthy thanked shareholders, staff, and partners including CNRS and Avion for their continued support.